NasdaqGM:KOD 1 Year Share Price vs Fair Value Explore Kodiak Sciences's Fair Values from the Community and select ...

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that ...

Barclays raised the firm’s price target on Kodiak Sciences (KOD) to $7 from $4 and keeps an Underweight rating on the shares. The company’s Q2 ...

Kodiak Sciences ( ($KOD) ) has released its Q2 earnings. Here is a breakdown of the information Kodiak Sciences presented to its investors. Kodiak ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

--Kodiak Sciences Inc., today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said ...

PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended ...

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases.

KSI-301 is being developed and is fully owned globally by Kodiak Sciences Inc. In December 2019, Kodiak entered into an agreement to sell a 4.5% capped royalty right on global net sales of KSI-301 ...

Kodiak Sciences develops new treatments for chronic, high-prevalence retinal diseases. The company expects the initial public offering price to be between $13.00 and $15.00 per share.

--Kodiak Sciences Inc., today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R ...